IDSA to Participate in World AMR Congress

The fourth annual World Antimicrobial Resistance Congress will bring 150 speakers and 400 stakeholders to Washington, D.C., Oct. 25 and 26 to discuss critical challenges and opportunities to advance antibiotic and diagnostics development, improve antimicrobial stewardship practice, and incentivize funding and partnering to bring innovation to patients and the healthcare system in need.

In addition to IDSA representatives, the conference is gathering hospital executives, investors, government employees, regulators, international organizations, funding agencies and solution providers including Achaogen, AMR Centre, CARB-X, the FDA, Merck, Melinta Therapeutics, NIH-NIAD, Children’s National Health System, City of Hope, Biofilm Pharma and others.

The congress will have four tracks: Antibiotic R&D, Diagnostics, Antimicrobial Stewardship and an Innovation Showcase.

IDSA’s participation:

Keynote: IDSA President Paul Auwaerter, MD, MBA, FIDSA

The Other Pipeline Problem - Where are the AMR Experts? 

• Challenges facing the recruitment and retention of clinicians, scientists and public health leaders to address AMR
• How workforce threats impact care of patients with resistant infections, stewardship, and research & development
• Policy recommendations to secure the future AMR workforce

Keynote Panel – Amanda Jezek Participating

Coordinated Pull – engaging all stakeholders to make “pull” incentives a reality

Other participants include BIO, Basiliea Pharmaceutica, Norwegian Institute of Public Health, Wellcome Trust, and Merck & Co

Roundtable — Led by Amanda Jezek

Engaging Policymakers- Successful strategies to focus policymaker attention on AMR and build political will for advancing incentives, stewardship and additional policies and investments

IDSA members can receive a 20% discount on registration by visiting: http://bit.ly/2xJ2Nom, and entering the promo code IDSA20 at checkout.